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Objective: Despite the apparent familial tendency toward abdominal aortic aneurysm (AAA) formation, the genetic causes
and underlying molecular mechanisms are still undeﬁned. In this study, we investigated the association between familial
AAA (fAAA) and atherosclerosis.
Methods: Data were collected from a prospective database including AAA patients between 2004 and 2012 in the Erasmus
University Medical Center, Rotterdam, The Netherlands. Family history was obtained by written questionnaire (93.1%
response rate). Patients were classiﬁed as fAAA when at least one affected ﬁrst-degree relative with an aortic aneurysm was
reported. Patients without an affected ﬁrst-degree relative were classiﬁed as sporadic AAA (spAAA). A standardized
ultrasound measurement of the common carotid intima-media thickness (CIMT), a marker for generalized atheroscle-
rosis, was routinely performed and patients’ clinical characteristics (demographics, aneurysm characteristics, cardiovas-
cular comorbidities and risk factors, and medication use) were recorded. Multivariable linear regression analyses were
used to assess the mean adjusted difference in CIMT and multivariable logistic regression analysis was used to calculate
associations of increased CIMT and clinical characteristics between fAAA and spAAA.
Results: A total of 461 AAA patients (85% men, mean age, 70 years) were included in the study; 103 patients (22.3%) were
classiﬁed as fAAA and 358 patients (77.7%) as spAAA. The mean (standard deviation) CIMT in patients with fAAA was
0.89 (0.24) mm and 1.00 (0.29) mm in patients with spAAA (P[ .001). Adjustment for clinical characteristics showed
a mean difference in CIMT of 0.09 mm (95% conﬁdence interval, 0.02-0.15; P[ .011) between both groups. Increased
CIMT, smoking, hypertension, and diabetes mellitus were all less associated with fAAA compared with spAAA.
Conclusions: The current study shows a lower atherosclerotic burden, as reﬂected by a lower CIMT, in patients with fAAA
compared with patients with spAAA, independent of common atherosclerotic risk factors. These results support the
hypothesis that although atherosclerosis is a common underlying feature in patients with aneurysms, atherosclerosis is not
the primary driving factor in the development of fAAA (J Vasc Surg 2014;59:589-93.)Abdominal aortic aneurysm (AAA) is characterized by
inﬁltration of inﬂammatory cells, loss of vascular smooth
muscle cells, and extracellular matrix degeneration in the
aortic wall.1 While the causality has been challenged,
AAA is associated with atherosclerosis.2,3 Approximately
20% of patients with an AAA have a ﬁrst-degree relative
diagnosed with an aortic aneurysm.4 Despite the apparent
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In this study, we investigated the association between
familial AAA (fAAA) and atherosclerosis. To this end, we
assessed the common carotid intima-media thickness
(CIMT) in patients with AAA using B-mode ultrasonog-
raphy. Thickening of the intimal and medial layers of the
common carotid artery is an early expression of generalized
atherosclerosis.6,7 We evaluated the difference in CIMT
between patients with a genetic predisposition to AAA
(ie, patients with fAAA) and patients with sporadic
AAA (spAAA), correcting for clinical characteristics.
Furthermore, we investigated whether CIMT could serve
as a clinical marker to identify patients with fAAA in our
population.
METHODS
Study population. The study population consisted of
patients with an AAA, deﬁned as an external maximum
transverse abdominal aortic diameter $30 mm,8 who
underwent either elective open or endovascular repair or
remained under surveillance between 2004 and 2012 at the
Erasmus University Medical Center in Rotterdam, The
Netherlands. The database included a total of 780 patients
with AAA. Between 2009 and 2012, all AAA patients were589
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asked to complete a semistructured questionnaire, to
collect personal data and family histories, and return the
questionnaire by mail. Patients who did not respond after
one reminder, were contacted and interviewed by tele-
phone (K.vdL.). In families with multiple AAA patients,
only one index patient (ie, ﬁrst family member diagnosed
with AAA) was included in the study. Patients diagnosed
with a known genetic aortic aneurysm syndrome (eg,
Marfan, Loeys-Dietz, or vascular Ehlers-Danlos syndrome)
were excluded. The study complied with the declaration of
Helsinki and was approved by the Institutional Review
Board.
Questionnaire and classiﬁcation of fAAA. The ques-
tionnaire requested information on demographics and the
medical history of the index patient. Furthermore, struc-
tured questions were included on the occurrence of aortic
aneurysms and cardiovascular disease for all known relatives
of the index patient. Patients were classiﬁed as fAAA when
at least one ﬁrst-degree relative (parents, siblings, or chil-
dren) was reported to have an aortic aneurysm. Patients
who did not report a ﬁrst-degree relative affected with AAA
were classiﬁed as spAAA. Patients reporting only second- or
third-degree relatives were also classiﬁed as spAAA because
the reporting of medical information of second- or third-
degree relatives was considered less reliable.
Clinical characteristics. Patients were prospectively
enrolled and the following characteristics were recorded
for all patients as part of routine clinical practice, including
sex, age, body mass index, as well as aneurysm characteris-
tics and the cardiovascular comorbidities and risk factors.
Aneurysm characteristics included maximal aneurysm
diameter and rupture rate. Cardiovascular comorbidities
included congestive heart failure, ischemic heart disease
(history of myocardial infarction, angina pectoris, coro-
nary revascularization or pathologic Q-waves on the elec-
trocardiogram), and cerebrovascular disease (history of
ischemic/hemorrhagic stroke or transient ischemic attack).
Cardiovascular risk factors included kidney disease (serum
creatinine $2.0 mg/dL), diabetes mellitus (fasting plasma
glucose $7.0 mmol/L, non-fasting glucose $11.1 mmol/L
or use of antidiabetic medication), hypertension (blood
pressure$140/90 mmHg in nondiabetics,$130/80 mm
Hg in diabetics or use of antihypertensive medication), and
hypercholesterolemia (low-density lipoprotein cholesterol
$3.5 mmol/L or use of lipid lowering medication).
Smoking status was obtained and included current smoking
and ever smoking (ie, patients who are currently smoking
OR patients with a history of smoking). Prescription
medication was recorded, including statins, beta-blockers,
renin-angiotensin system inhibitors, diuretics, and anti-
platelet drugs. Serum concentrations of the inﬂammatory
biomarker high-sensitivity C-reactive protein were mea-
sured using immunochemistry (Beckman Coulter, Woer-
den, The Netherlands).
Atherosclerotic marker. The severity of atheroscle-
rotic disease was assessed by measurements of the CIMT
using B-mode ultrasonography according to the guidelinesfrom the “Mannheim Carotid Intima-Media Thickness
Consensus.”9,10 Patients were examined in the supine
position with the head turned 45 away from the side being
scanned and the neck extended slightly. A longitudinal
view of the right and left common carotid artery was ob-
tained by a portable Sonosite Titan Ultrasound System
(Sonosite Inc, Bothell, Wash) with a L38-10-5 MHz linear
ultrasound transducer or a portable Vivid-I Ultrasound
System (Vivid-I; GE Healthcare, Solingen, Germany) with
an 8L-RS transducer. Several measurements were made
along a minimum of 10 mm at the posterior wall of the
right and left common carotid artery. The intima-media
thickness was calculated online by built-in software of the
ultrasound system from the interface between lumen and
intima to the interface between media and adventitia. The
maximum CIMT value of both common carotid arteries
was used for the analysis. Atherosclerotic plaques, deﬁned
as focal structures of at least 0.5 mm encroaching into the
arterial lumen, were excluded from analysis.10 The sonog-
raphers who performed the measurements were blinded for
the clinical characteristics of the patients and had an
interobserver correlation of 96.2%.9
Statistical analysis. Dichotomous data are presented as
numbers and percentages. Continuous variables are pre-
sented asmean (standard deviation) ormedian (interquartile
range)when not normally distributed. Categorical data were
analyzed with chi-square test, and continuous variables with
analysis of variance or Kruskal-Wallis test, as appropriate.
Multivariable linear regression analysis was performed to
assess the mean adjusted difference in CIMT between fAAA
and spAAA. The CIMT was used as dependent variable and
we adjusted for age #65 years at diagnosis, sex, body mass
index, congestive heart failure, ischemic heart disease,
cerebrovascular disease, kidney disease, diabetes mellitus,
hypercholesterolemia, hypertension, ever smoking, and
high-sensitivity C-reactive protein. Additional analysis was
performed using previous adjustments plus medication.
Covariates were chosen on the basis of biological plausi-
bility. Multivariable binary logistic regression analysis was
used to calculate the associations of increased CIMT (per
mm) and clinical characteristics between fAAA and spAAA.
Covariates in themodel were the same clinical characteristics
as used in the multivariable linear regression analysis. To
assess any selection bias, baseline characteristics for patients
with and without (ie, those excluded from the study) CIMT
measurement were analyzed with c2 tests. For all tests,
a P value of < .05 (two-sided) was considered signiﬁcant.
All analyses were performed using IBM SPSS Statistics v.
20.0 (SPSS Inc, Chicago, Ill).
RESULTS
The questionnaire was presented to 610 AAA patients,
and 482 patients (79.0%) responded after one reminder. Of
the remaining 128 patients who did not return the ques-
tionnaire, 10 patients were deceased, 108 were interviewed
by telephone, and 10 could not be reached. Twenty-two
AAA patients were related to other AAA patients partici-
pating in the study and were excluded. In this way, family
Table I. Clinical characteristics of patients with familial abdominal aortic aneurysm (fAAA) and sporadic AAA (spAAA)
Variablea
Total population fAAA spAAA
P value(N ¼ 461) (n ¼ 103) (n ¼ 358)
Male sex 390 (84.6) 82 (79.6) 308 (86.0) .112
Age at diagnosis, years 69.7 (8.0) 67.8 (8.0) 70.2 (7.9) .007
Age #65 years at diagnosis 141 (30.6) 40 (38.8) 101 (28.2) .039
Body mass index, kg/m2 26.3 (4.2) 26.5 (4.7) 26.3 (4.0) .707
Aneurysm characteristics
Aneurysm diameter, mmb 59.6 (14.2) 56.9 (15.1) 60.3 (13.9) .036
Ruptured aneurysm 59 (12.8) 17 (16.5) 42 (11.7) .201
Cardiovascular comorbidities
Congestive heart failure 119 (25.8) 30 (29.1) 89 (24.9) .383
Ischemic heart disease 209 (45.3) 46 (44.7) 163 (45.5) .879
Cerebrovascular disease 101 (21.9) 23 (22.3) 78 (21.8) .907
Cardiovascular risk factors
Kidney disease 96 (20.8) 20 (19.4) 76 (21.2) .690
Diabetes mellitus 90 (19.5) 13 (12.6) 77 (21.5) .045
Hypertension 363 (78.7) 71 (68.9) 292 (81.5) .005
Hypercholesterolemia 437 (94.8) 94 (91.3) 343 (95.8) .067
Smokingecurrent 207 (44.9) 44 (42.7) 163 (45.5) .613
Smokingeever 422 (91.5) 87 (84.5) 335 (93.6) .003
Medication
Statin 361 (78.3) 76 (73.8) 285 (79.6) .206
Beta-blocker 410 (88.9) 89 (86.4) 321 (89.7) .353
Renin-angiotensin system inhibitor 267 (57.9) 60 (58.3) 207 (57.8) .938
Diuretic 145 (31.5) 34 (33.0) 111 (31.0) .699
Antiplatelet drug 382 (82.9) 81 (78.6) 301 (84.1) .197
Inﬂammation marker
High-sensitivity C-reactive protein, mg/L 5.3 [2.6-10.3] 5.2 [2.9-9.9] 5.3 [2.6-10.6] .793
Atherosclerotic marker
CIMT, mm 0.97 (0.28) 0.89 (0.24) 1.00 (0.29) .001
CIMT, Common carotid intima-media thickness.
aContinuous data are presented as the mean (standard deviation) or median [interquartile range] and categorical data as number (%).
bAneurysm diameters were available for 436 patients.
Table II. Differences in common carotid intima-media
thickness (CIMT) between familial abdominal aortic
aneurysm (fAAA) and sporadic AAA (spAAA)
Atherosclerotic
marker b 95% CI for b P value
CIMT Unadjusted 0.10 0.04:0.16 .001
Adjusteda 0.09 0.02:0.15 .011
Adjustedb 0.09 0.03:0.16 .007
BMI, Body mass index; CI, conﬁdence interval.
aAdjusted for age #65 years at diagnosis, sex, BMI, congestive heart failure,
ischemic heart disease, cerebrovascular disease, kidney disease, diabetes
mellitus, hypercholesterolemia, hypertension, ever smoking and high-
sensitivity C-reactive protein.
bAdjusted fora and medication.
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a 93.1% response rate. The ﬁnal study population consisted
of 461 of these patients (81.2%) in whom the CIMT was
determined.
In total, 103 AAA patients (22.3%) reported to have at
least one ﬁrst-degree relative diagnosed with aortic aneu-
rysm and were classiﬁed as fAAA. The remaining 358
patients (77.7%) without ﬁrst-degree relatives with an
aortic aneurysm were classiﬁed as spAAA. Clinical charac-
teristics are presented in Table I. Maximal aneurysm diam-
eters were smaller in patients with fAAA, and there was no
difference in ruptured AAA rates between the two groups.
Furthermore, patients with fAAA were younger and had
a lower prevalence of diabetes mellitus, hypertension, and
were less likely to have ever smoked. No signiﬁcant differ-
ences were observed in the use of prescription medication
and serum high-sensitivity C-reactive protein levels.
Atherosclerotic marker. The mean CIMT in patients
with fAAA was 0.89 (0.24) mm and 1.00 (0.29) mm in
patients with spAAA (P ¼ .001). Univariable regression
analysis showed a mean difference in CIMT of 0.10 mm
(95% conﬁdence interval [CI], 0.04-0.16; P ¼ .001;
Table II). After adjustment for potentially confounding
factors, the difference in CIMT decreased to 0.09 mm
(95% CI, 0.02-0.15; P ¼ .011). Additional adjustment for
medication showed comparable results.Associations with fAAA and spAAA. Multivariable
binary logistic regression analysis showed that increased
CIMT (odds ratio [OR], 0.27; 95% CI, 0.10-0.73;
P ¼.010), ever smoking (OR, 0.32; 95% CI, 0.38-0.72;
P ¼ .006), hypertension (OR, 0.38; 95% CI, 0.21-0.67;
P ¼.001), as well as diabetes mellitus (OR, 0.48; 95%
CI, 0.23-1.00; P ¼ .049), were all less associated with
fAAA (Fig).
Assessment of selection bias. We observed a differ-
ence in characteristics between patients included and
Fig. Multivariable logistic analysis for familial abdominal aortic
aneurysm (fAAA) and sporadic AAA (spAAA). Included in model
are age #65 years at diagnosis, sex, body mass index (BMI),
congestive heart failure, ischemic heart disease, cerebrovascular
disease, kidney disease, diabetes mellitus, hypercholesterolemia,
hypertension, ever smoking, and high-sensitivity C-reactive
protein. CI, Conﬁdence interval; CIMT, common carotid intima-
media thickness; OR, odds ratio.
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ysis for age (included, 70 years vs excluded, 67 years;
P ¼.002), congestive heart failure (included, 25.8% vs
excluded, 9.3%; P < .001) and hypertension (included,
78.9% vs excluded, 66.4%; P ¼.006). There was no differ-
ence in the percentage of patients classiﬁed as fAAA
(included, 22.3% vs excluded, 23.4%; P ¼ .820).
DISCUSSION
This study shows that the CIMT was lower in patients
with fAAA than in patients with spAAA. Although patients
with fAAA had a more favorable cardiovascular risk proﬁle
(ie, younger age, less hypertension, and less diabetes melli-
tus), which may have inﬂuenced the results, the CIMT
remained signiﬁcantly lower after adjustment for these
factors in multivariable analysis. These ﬁndings indicate
that the atherosclerotic burden is lower in patients with
a familial form of AAA and suggest a difference in pathobi-
ology between patients with fAAA and spAAA.
Thickening of the intimal and medial layers of the
common carotid artery is an early expression of generalized
atherosclerosis.6,11 General cardiovascular risk factors, such
as hypertension, smoking, diabetes mellitus, and dyslipide-
mia, are associated with an increased CIMT.12 In addition,
an elevated CIMT is associated with atherosclerotic
diseases,7 as well as with ischemic events.13,14 A systematic
review by Aminbakhsh et al has revealed that the risk of
a ﬁrst myocardial infarction increases with a CIMT of
0.82 mm or higher and the risk of a ﬁrst stroke with
a CIMT of 0.75 mm or higher.14 Hence, the CIMT is
considered a valuable tool to assess early atherosclerosis.
In the current study, the mean CIMT was 0.89 mm in
patients with fAAA and 1.00 mm in patients with spAAA,
with a mean difference of 0.09 mm between the groups
after adjusting for cardiovascular comorbidities and risk
factors, medication use, and the inﬂammatory marker
high-sensitivity C-reactive protein. It has been shown
that a rise in CIMT of 0.03 mm per year is associated
with a signiﬁcant increase in ischemic events and that an
absolute CIMT difference of 0.1 mm increases the future
risk for myocardial infarction by 10%-15% and the risk for
stroke by 13%-18%.14,15 This suggests that the observed
0.09 mm difference in CIMT reﬂects a lower atheroscle-
rotic load in fAAA patients.
We recently reported that patients with aneurysmal
disease have a lower CIMT compared with patients with
occlusive arterial disease (0.97 mm vs 1.07 mm, respec-
tively),16 which is in line with several previous studies.17-19
We now show that patients with a familial form of AAA
have an even lower CIMT than AAA patients without
affected relatives. Compared with the healthy aged popula-
tion, the Rotterdam study showed that the mean CIMT in
patients with a mean age of 71 years was 0.79 mm and
another study with participants from the United Kingdom
over the age of 60 years showed a CIMT of 0.81 mm.20,21
Consequently, patients with fAAA still have higher CIMT
values compared with previously reported CIMT values
in the general population, indicating that our patientswith AAA were not free of atherosclerosis. Our results
further strengthen the idea that even if atherosclerosis
may inﬂuence the evolution and development of aneu-
rysms, other factors account for divergent pathophysiologic
mechanisms underlying familial and sporadic aneurysmal
disease.
Although not statistically signiﬁcant, we observed
a trend toward more females affected with fAAA compared
with spAAA. A difference in sex was also observed by
Darling et al and supports the hypothesis that female
AAA patients may have a higher genetic susceptibility for
AAA than males.22
Although we did observe a signiﬁcant difference in
CIMT, the high standard deviations and considerable over-
lap in CIMT between the two groups precludes the clinical
use of CIMT measurements for differentiating reliably
fAAA from spAAA patients.
Our study has some limitations. First, an important
difﬁculty with the CIMT measurement is the lack of
uniformity in its deﬁnition and the methodology used,
which limits quantitative comparisons of absolute CIMT
values between studies.10 Second, the deﬁnition of fAAA
is based on family history and underestimating fAAA is
likely because of under-reporting of affected relatives and
the likelihood of having affected relatives is lower in smaller
families. Third, since no systematic molecular screening
was performed of the genes associated with Marfan,
Loeys-Dietz, or vascular Ehlers-Danlos syndrome, patients
with speciﬁc genetic aneurysm syndromes might have been
JOURNAL OF VASCULAR SURGERY
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rare causes for AAA, the contribution of these syndromes
to the study population is probably very small. Last,
because CIMT values were obtained in 81.2% of the
AAA patients, we cannot exclude the possibility of selection
bias. However, because there was no difference in the
percentage of patients classiﬁed as fAAA, we believe that
any potential selection bias was equally divided between
the two patient populations and does not hamper the ﬁnd-
ings of the study.
CONCLUSIONS
The current study shows a lower atherosclerotic
burden, as reﬂected by a lower CIMT, in patients with
fAAA compared with patients with spAAA, independent
of common atherosclerotic risk factors. These results
support the hypothesis that although atherosclerosis is
a common underlying feature in patients with aneurysms,
atherosclerosis is not the primary driving factor in the
development of fAAA. Further research on the molecular
pathways and genetics of aortic aneurysm formation is war-
ranted to identify the cause(s) of fAAA and spAAA.
AUTHOR CONTRIBUTIONS
Conception and design: KL, RS, DM, HV, ER
Analysis and interpretation: KL, SH
Data collection: KL, FB, TV
Writing the article: KL, FB, SH, RS, HV
Critical revision of the article: TV, DM, HV, ER
Final approval of the article: KL, FB, SH, TV, RS, DM,
HV, ER
Statistical analysis: KL, FB, SH
Obtained funding: RS, HV
Overall responsibility: HV
REFERENCES
1. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysi-
ology and epidemiology of abdominal aortic aneurysms. Nat Rev
Cardiol 2011;8:92-102.
2. Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms
caused by atherosclerosis? Circulation 1992;85:205-11.
3. Johnsen SH, Forsdahl SH, Singh K, Jacobsen BK. Atherosclerosis in
abdominal aortic aneurysms: a causal event or a process running in
parallel? The Tromso Study. Arterioscler Thromb Vasc Biol 2010;30:
1263-8.
4. Salo JA, Soisalon-Soininen S, Bondestam S, Mattila PS. Familial
occurrence of abdominal aortic aneurysm. Ann Intern Med 1999;130:
637-42.
5. Kuivaniemi H, Shibamura H, Arthur C, Berguer R, Cole CW,
Juvonen T, et al. Familial abdominal aortic aneurysms: collection of
233 multiplex families. J Vasc Surg 2003;37:340-5.
6. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ,
Fruchart JC, et al. Measurement of arterial wall thickness as a surrogate
marker for atherosclerosis. Circulation 2004;109(23 Suppl 1):III33-8.
7. Allan PL, Mowbray PI, Lee AJ, Fowkes FG. Relationship between
carotid intima-media thickness and symptomatic and asymptomaticperipheral arterial disease. The Edinburgh Artery Study. Stroke
1997;28:348-53.
8. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M,
et al. Management of abdominal aortic aneurysms clinical practice
guidelines of the European society for vascular surgery. Eur J Vasc
Endovasc Surg 2011;41(Suppl 1):S1-58.
9. Flu WJ, van Kuijk JP, Hoeks SE, Kuiper R, Schouten O, Goei D, et al.
Intima media thickness of the common carotid artery in vascular
surgery patients: a predictor of postoperative cardiovascular events. Am
Heart J 2009;158:202-8.
10. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P,
Bornstein N, et al. Mannheim carotid intima-media thickness
consensus (2004-2006). An update on behalf of the Advisory Board of
the 3rd and 4th Watching the Risk Symposium, 13th and 15th
European Stroke Conferences, Mannheim, Germany, 2004, and
Brussels, Belgium, 2006. Cerebrovasc Dis 2007;23:75-80.
11. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL,
Wolfson SK Jr. Carotid-artery intima and media thickness as a risk
factor for myocardial infarction and stroke in older adults. Cardiovas-
cular Health Study Collaborative Research Group. N Engl J Med
1999;340:14-22.
12. Cheng KS, Mikhailidis DP, Hamilton G, Seifalian AM. A review of the
carotid and femoral intima-media thickness as an indicator of the
presence of peripheral vascular disease and cardiovascular risk factors.
Cardiovasc Res 2002;54:528-38.
13. Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA,
D’Agostino RB Sr. Carotid-wall intima-media thickness and cardio-
vascular events. N Engl J Med 2011;365:213-21.
14. Aminbakhsh A, Mancini GB. Carotid intima-media thickness
measurements: what deﬁnes an abnormality? A systematic review. Clin
Invest Med 1999;22:149-57.
15. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of
clinical cardiovascular events with carotid intima-media thickness:
a systematic review and meta-analysis. Circulation 2007;115:459-67.
16. van de Luijtgaarden KM, Bakker EJ, Rouwet EV, Hoeks SE,
Valentijn TM, Stolker RJ, et al. Aneurysmal disease is associated with
lower carotid intima-media thickness than occlusive arterial disease.
J Vasc Surg 2013;57:642-7.
17. Simons PC, Algra A, Bots ML, Banga JD, Grobbee DE, van der
Graaf Y. Common carotid intima-media thickness in patients with
peripheral arterial disease or abdominal aortic aneurysm: the SMART
study. Second Manifestations of ARTerial disease. Atherosclerosis
1999;146:243-8.
18. Spring S, van der Loo B, Krieger E, Amann-Vesti BR, Rousson V,
Koppensteiner R. Decreased wall shear stress in the common carotid
artery of patients with peripheral arterial disease or abdominal aortic
aneurysm: relation to blood rheology, vascular risk factors, and intima-
media thickness. J Vasc Surg 2006;43:56-63; discussion: 63.
19. Cheuk BL, Lau SS, Cheng SW. Carotid intima-media thickness in
patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg
2007;33:149-53.
20. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common
carotid intima-media thickness and risk of stroke and myocardial
infarction: the Rotterdam Study. Circulation 1997;96:1432-7.
21. Lim TK, Lim E, Dwivedi G, Kooner J, Senior R. Normal value of
carotid intima-media thicknessda surrogate marker of atherosclerosis:
quantitative assessment by B-mode carotid ultrasound. J Am Soc
Echocardiogr 2008;21:112-6.
22. Darling RC III, Brewster DC, Darling RC, LaMuraglia GM,
Moncure AC, Cambria RP, et al. Are familial abdominal aortic aneu-
rysms different? J Vasc Surg 1989;10:39-43.Submitted Jun 10, 2013; accepted Aug 21, 2013.
